This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength
by Zacks Equity Research
Tyra Biosciences, Inc. (TYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 52.2% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Tyra Biosciences, Inc. (TYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 59.2% in Tyra Biosciences, Inc. (TYRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
by Zacks Equity Research
Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings?
by Zacks Equity Research
Tyra Biosciences (TYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184%
by Zacks Equity Research
The mean of analysts' price targets for Tyra Biosciences, Inc. (TYRA) points to an 184.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 178.5% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.